Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424

Article  PubMed  Google Scholar 

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236

Article  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905

Article  CAS  PubMed  Google Scholar 

Kulkarni AV, Tevethia H, Kumar K, Premkumar M, Muttaiah MD, Hiraoka A, et al. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. EClinical Med. 2023. https://doi.org/10.1016/j.eclinm.2023.102179

Article  Google Scholar 

Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599–1611

Article  CAS  PubMed  Google Scholar 

Myojin Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y, et al. Interleukin-6 Is a circulating prognostic biomarker for hepatocellular carcinoma patients treated with combined immunotherapy. Cancers (Basel). 2022;14(4):883

Article  CAS  PubMed  Google Scholar 

Matsumae T, Kodama T, Myojin Y, Maesaka K, Sakamori R, Takuwa A, et al. Circulating cell-free dna profiling predicts the therapeutic outcome in advanced hepatocellular carcinoma patients treated with combination immunotherapy. Cancers (Basel). 2022;14(14):3367

Article  CAS  PubMed  Google Scholar 

Ogawa K, Kanzaki H, Chiba T, Ao J, Qiang N, Ma Y, et al. Effect of Atezolizumab plus bevacizumab in patients with hepatocellular carcinoma harboring CTNNB1 mutation in early clinical experience. J Cancer. 2022;13(8):2656–2661

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hosoda S, Suda G, Sho T, Ogawa K, Kimura M, Yang Z, et al. Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment. Liver Cancer. 2022;12(2):156–170

Article  PubMed  PubMed Central  Google Scholar 

Li Y, Porta-Pardo E, Tokheim C, Bailey MH, Yaron TM, Stathias V, et al. Pan-cancer proteogenomics connects oncogenic drivers to functional states. Cell. 2023;186(18):3291-3944.e25

Article  Google Scholar 

Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res. 2019;25(7):2021–2023

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al. Genomic profile of advanced breast cancer in circulating tumour DNA. Nat Commun. 2021;12(1):2423

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73(6):1460–1469

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10

Article  PubMed  Google Scholar 

Guo M, Qi F, Rao Q, Sun J, Du X, Qi Z, et al. Serum LAG-3 predicts outcome and treatment response in hepatocellular carcinoma patients with transarterial chemoembolization. Front Immunol. 2021;12: 754961

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, et al. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. Br J Cancer. 2015;113(5):756–762

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cui X, Li Z, Gao J, Gao PJ, Ni YB, Zhu JY. Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a. Oncotarget. 2016;7(40):65052–65066

Article  PubMed  PubMed Central  Google Scholar 

Hayashi T, Yamashita T, Terashima T, Suda T, Okada H, Asahina Y, et al. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study. BMC Cancer. 2017;17(1):870

Article  PubMed  PubMed Central  Google Scholar 

Nahon P, Sutton A, Rufat P, Simon C, Trinchet JC, Gattegno L, et al. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol. 2008;14(5):713–719

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duan Z, Gao J, Zhang L, Liang H, Huang X, Xu Q, et al. Phenotype and function of CXCR5+CD45RA-CD4+ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis. Oncotarget. 2015;6(42):44239–44253

Article  PubMed  PubMed Central  Google Scholar 

Tada T, Kumada T, Hiraoka A, Kariyama K, Tani J, Hirooka M, et al. Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Oncology. 2023;101(4):270–282

Article  CAS  PubMed  Google Scholar 

Sogbe M, Bilbao I, Marchese FP, Zazpe J, Vito A, Pozuelo M, et al. Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment. Clin Mol Hepatol. 2023. https://doi.org/10.3350/cmh.2023.0426

Article  PubMed  PubMed Central  Google Scholar 

Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021. https://doi.org/10.1016/j.cell.2021.01.002

Article  PubMed  PubMed Central  Google Scholar 

Masuhiro K, Tamiya M, Fujimoto K, Koyama S, Naito Y, Osa A, et al. Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer. JCI Insight. 2022;7(9): e157915

Article  PubMed  PubMed Central  Google Scholar 

Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune. Regulation Immunity. 2016;44(5):989–1004

Article  CAS  PubMed  Google Scholar 

Kisielow M, Kisielow J, Capoferri-Sollami G, Karjalainen K. Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells. Eur J Immunol. 2005;35(7):2081–2088

Article  CAS  PubMed  Google Scholar 

Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol. 2023;24(9):1415–1422

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Y, Ding L, Li H, Peng Z, Ding K, Huang Z, et al. Serum cytokine analysis in a cohort of advanced non-small cell lung cancer treated with PD-1 inhibitors reveals predictive markers of CXCL12. Front Immunol. 2023;14:1194123. https://doi.org/10.3389/fimmu.2023.1194123

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Su W, Tang D, Jing J, Xiong J, Deng Y, et al. An immune-related gene prognostic index for triple-negative breast cancer integrates multiple aspects of tumor-immune microenvironment. Cancers. 2021;13(21):5342

Article  CAS  PubMed